At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jun 1, 2026 at 08:30 ET
Fate Therapeutics presented early Phase 1 data for FT836, an off-the-shelf CAR T-cell therapy targeting MICA/B in solid tumors, at ASCO 2026. In two heavily pre-treated KRASwt metastatic colorectal cancer patients, FT836 plus cetuximab without conditioning chemotherapy showed a 19% tumor reduction (Case 1) and a 52% liver lesion reduction (Case 2), with no DLTs, CRS, ICANS, or GvHD across nine patients. The data demonstrate first-in-human proof of trafficking and persistence in tumor tissue without lymphodepletion, but the sample is tiny (n=9 safety, n=5 efficacy-evaluable, n=2 with anti-tumor activity) and early-stage, limiting immediate stock-moving impact.
- FT836 is an off-the-shelf, iPSC-derived CAR T-cell targeting MICA/B with Sword & Shield technology to eliminate need for conditioning chemotherapy.
- Nine patients enrolled across two regimens (FT836 + cetuximab, n=6; FT836 + trastuzumab, n=3); no DLTs, CRS, ICANS, or GvHD observed.
- Five patients available for efficacy; two KRASwt mCRC patients with 7 prior lines each showed tumor reduction: 19% sum-of-diameters (Case 1) and 52% liver lesion reduction (Case 2).
- FT836 detected in peripheral blood (peak Day 4) and tumor tissue (Day 22 biopsy) without conditioning chemotherapy, with evidence of tumor immune microenvironment remodeling.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access